Researchers found that DNA mutations from antiviral enzymes and chemotherapy fuel early bladder cancer, while abnormal circular DNA in tumor cells drives resistance to therapy. These discoveries open new therapeutic avenues.
A groundbreaking study led by researchers at Weill Cornell Medicine and the New York Genome Center has provided unprecedented insights into how bladder cancer begins and progresses. The team discovered that antiviral enzymes, which mutate the DNA of both normal and cancer cells, are key promoters of early bladder cancer development, and that standard chemotherapy is also a potent source of mutations.
The researchers also discovered that overactive genes within abnormal circular DNA structures in tumor cells genes drive bladder cancer resistance to therapy. These findings are novel insights into bladder cancer biology and point to new therapeutic strategies for this difficult-to-treat cancer.
The study, published recently in Nature, focused on the main form of bladder cancer, urothelial carcinoma, which originates from cells that line the bladder, urethra, and tubes that drain urine from the kidneys. The researchers examined malignant and pre-malignant urothelial cells taken from the same set of patients at different disease stages. They used whole-genome sequencing and advanced computational methods to map common DNA mutations, complex structural variants, and their timing.
"Our findings define new fundamental mechanisms driving bladder cancer evolution—mechanisms that we can now think about targeting with therapies," said co-senior author Dr. Bishoy Faltas, the Gellert Family–John P. Leonard MD Research Scholar in Hematology and Medical Oncology and an associate professor of medicine and of cell and developmental biology at Weill Cornell Medicine, and an oncologist at NewYork-Presbyterian/Weill Cornell Medical Center.
Dr. Nicolas Robine, director of computational biology at the New York Genome Center, and Dr. Olivier Elemento, director of the Englander Institute for Precision Medicine and a professor of physiology and biophysics at Weill Cornell Medicine, also led the study with Dr. Faltas. The co-first authors were Duy Nguyen, a technician in the Faltas Laboratory (now a doctoral student at Harvard Medical School); William Hooper, a bioinformatics scientist at the New York Genome Center; and Dr. Weisi Liu, an instructor in the Faltas Laboratory.
Major Therapeutic Targets Come into Focus
Bladder cancer occurs at the rate of about 80,000 cases per year in the United States. It can be cured with surgery if caught early, but about 30 percent of cases are diagnosed at later stages when it is much harder to treat successfully.
The researchers in the new study found strong evidence that the APOBEC3 enzymes cause early mutations that may help trigger the development of this cancer type. These enzymes evolved to disable infecting retroviruses by editing their viral DNA, though it is known that they can sometimes mutate cells' own DNA.
"The exact role of APOBEC3-induced mutations in cancer initiation hasn't been clear," said Dr. Faltas, who is also the chief research officer at the Englander Institute for Precision Medicine and a member of the Sandra and Edward Meyer Cancer Center at Weill Cornell Medicine. "But we found that these mutations appear early in urothelial cancer, occurring even in pre-malignant urothelial tissue." In his lab, Dr. Faltas is focusing on studying the role of these mutagenic enzymes in driving cancer evolution.
The researchers found that cisplatin and other platinum-based chemotherapies cause further prominent bursts of mutations, some of which likely allow urothelial cancer cells to survive better and spread despite treatment.
A third major finding was that urothelial tumors often contain complex rearrangements of their DNA that give rise to circular segments of DNA. These "extra-chromosomal DNAs" (ecDNAs) exist apart from chromosomes in the cell nucleus and can sometimes harbor hundreds of copies of cancer-driving growth genes. The researchers discovered that these ecDNA events persist and become more complex, incorporating new DNA segments after treatment, suggesting that they drive resistance to therapy.
This prompted the team to experimentally model an ecDNA version of one of these genes, called CCND1, a master regulator of the cell cycle in the laboratory. The results of these experiments confirmed that CCND1 in this extrachromosomal configuration drives treatment resistance.
Altogether, the findings paint a much clearer picture of the factors that trigger and drive urothelial cancer.
"Traditionally, when analyzing tumor genomes, we've used methods that analyze only a tiny fraction of their DNA, but we've come to realize that there's a lot more to discover if we sequence all their DNA and use smart methods to evaluate that data," Dr. Elemento said. "I think this collaboration vindicates that strategy."
The Englander Institute and New York Genome Center researchers are planning larger future collaborative studies to dig even deeper into urothelial cancer biology, for example, doing whole-genome sequencing of DNA along with readouts of gene activity not just in bulk tumor samples but in individual tumor cells.
"Combining those two sets of information at the single-cell level would be tremendously important and interesting," Dr. Robine said.
The researchers also plan to study potential clinical applications of this work. The investigators are hopeful that a new FDA-approved drug targeting the ERBB2 gene product—the HER2 receptor protein, also found on breast tumor cells—will work especially well in urothelial cancer patients with strong signs of ERBB2 ecDNAs. They are also working on finding ways to block ecDNA formation and maintenance.
Reference: "The interplay of mutagenesis and ecDNA shapes urothelial cancer evolution" by Duy D. Nguyen, William F. Hooper, Weisi Liu, Timothy R. Chu, Heather Geiger, Jennifer M. Shelton, Minita Shah, Zoe R. Goldstein, Lara Winterkorn, Adrienne Helland, Michael Sigouros, Jyothi Manohar, Jenna Moyer, Majd Al Assaad, Alissa Semaan, Sandra Cohen, Florencia Madorsky Rowdo, David Wilkes, Mohamed Osman, Rahul R. Singh, Andrea Sboner, Henkel L. Valentine, Phillip Abbosh, Scott T. Tagawa, David M. Nanus, Jones T. Nauseef, Cora N. Sternberg, Ana M. Molina, Douglas Scherr, Giorgio Inghirami, Juan Miguel Mosquera, Olivier Elemento, Nicolas Robine and Bishoy M. Faltas, 9 October 2024, Nature.
DOI: 10.1038/s41586-024-07955-3
The research reported in this story was supported in part by the National Cancer Institute and the National Center for Advancing Translational Science, both part of the National Institutes of Health, through grant numbers R37CA279737, U01CA260369, UL1TR002384; and the United States Department of Defense through grant number W81XWH-17-1-0539. Additional support was provided by the Starr Cancer Consortium, the Leo & Anne Albert Institute for Bladder Cancer Care and Research, the Translational Research Program in the Department of Pathology and Laboratory Medicine at Weill Cornell Medicine, and the New York Genome Center's Polyethnic-1000 Initiative.
News
New book from NanoappsMedical Inc – Molecular Manufacturing: The Future of Nanomedicine
This book explores the revolutionary potential of atomically precise manufacturing technologies to transform global healthcare, as well as practically every other sector across society. This forward-thinking volume examines how envisaged Factory@Home systems might enable the cost-effective [...]
A Virus Designed in the Lab Could Help Defeat Antibiotic Resistance
Scientists can now design bacteria-killing viruses from DNA, opening a faster path to fighting superbugs. Bacteriophages have been used as treatments for bacterial infections for more than a century. Interest in these viruses is rising [...]
Sleep Deprivation Triggers a Strange Brain Cleanup
When you don’t sleep enough, your brain may clean itself at the exact moment you need it to think. Most people recognize the sensation. After a night of inadequate sleep, staying focused becomes harder [...]
Lab-grown corticospinal neurons offer new models for ALS and spinal injuries
Researchers have developed a way to grow a highly specialized subset of brain nerve cells that are involved in motor neuron disease and damaged in spinal injuries. Their study, published today in eLife as the final [...]
Urgent warning over deadly ‘brain swelling’ virus amid fears it could spread globally
Airports across Asia have been put on high alert after India confirmed two cases of the deadly Nipah virus in the state of West Bengal over the past month. Thailand, Nepal and Vietnam are among the [...]
This Vaccine Stops Bird Flu Before It Reaches the Lungs
A new nasal spray vaccine could stop bird flu at the door — blocking infection, reducing spread, and helping head off the next pandemic. Since first appearing in the United States in 2014, H5N1 [...]
These two viruses may become the next public health threats, scientists say
Two emerging pathogens with animal origins—influenza D virus and canine coronavirus—have so far been quietly flying under the radar, but researchers warn conditions are ripe for the viruses to spread more widely among humans. [...]
COVID-19 viral fragments shown to target and kill specific immune cells
COVID-19 viral fragments shown to target and kill specific immune cells in UCLA-led study Clues about extreme cases and omicron’s effects come from a cross-disciplinary international research team New research shows that after the [...]
Smaller Than a Grain of Salt: Engineers Create the World’s Tiniest Wireless Brain Implant
A salt-grain-sized neural implant can record and transmit brain activity wirelessly for extended periods. Researchers at Cornell University, working with collaborators, have created an extremely small neural implant that can sit on a grain of [...]
Scientists Develop a New Way To See Inside the Human Body Using 3D Color Imaging
A newly developed imaging method blends ultrasound and photoacoustics to capture both tissue structure and blood-vessel function in 3D. By blending two powerful imaging methods, researchers from Caltech and USC have developed a new way to [...]
Brain waves could help paralyzed patients move again
People with spinal cord injuries often lose the ability to move their arms or legs. In many cases, the nerves in the limbs remain healthy, and the brain continues to function normally. The loss of [...]
Scientists Discover a New “Cleanup Hub” Inside the Human Brain
A newly identified lymphatic drainage pathway along the middle meningeal artery reveals how the human brain clears waste. How does the brain clear away waste? This task is handled by the brain’s lymphatic drainage [...]
New Drug Slashes Dangerous Blood Fats by Nearly 40% in First Human Trial
Scientists have found a way to fine-tune a central fat-control pathway in the liver, reducing harmful blood triglycerides while preserving beneficial cholesterol functions. When we eat, the body turns surplus calories into molecules called [...]
A Simple Brain Scan May Help Restore Movement After Paralysis
A brain cap and smart algorithms may one day help paralyzed patients turn thought into movement—no surgery required. People with spinal cord injuries often experience partial or complete loss of movement in their arms [...]
Plant Discovery Could Transform How Medicines Are Made
Scientists have uncovered an unexpected way plants make powerful chemicals, revealing hidden biological connections that could transform how medicines are discovered and produced. Plants produce protective chemicals called alkaloids as part of their natural [...]
Scientists Develop IV Therapy That Repairs the Brain After Stroke
New nanomaterial passes the blood-brain barrier to reduce damaging inflammation after the most common form of stroke. When someone experiences a stroke, doctors must quickly restore blood flow to the brain to prevent death. [...]
